Stock BRPA NRX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
3.54 USD +12.74% Intraday chart for NRx Pharmaceuticals, Inc. +16.45% -23.04%
04-18 NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq MT
04-18 Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
AQ
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
AQ
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq
MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches
MT
Top Premarket Decliners
MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket
MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital
MT
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics
CI
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100
AQ
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
CI
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
AQ
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
CI
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Transcript : NRx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Apr 01, 2024
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
PR
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
PR
UPDATE, NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
AQ
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
PR
NRx Pharmaceutical's Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRPA Stock
  4. News NRx Pharmaceuticals, Inc.